To investigate the involvement of PRMT1 in COPD, we analyzed the expression levels of PRMTs, using GEO database from normal and COPD patients (GSE57148).[17] We found that PRMT1 and PECAM1, a well‐known marker for ECs, are reduced in lungs from COPD patients, while other PRMTs showed no detectable expression or significant differences (Figure S1D, Supporting Information). Here, PECAM1 is linked to chronic obstructive pulmonary disease.